Intrexon (NYSE:XON) issued its earnings results on Thursday. The biotechnology company reported ($0.44) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.21), Briefing.com reports. The firm had revenue of $32.45 million for the quarter, compared to analyst estimates of $35.98 million. The business’s revenue for the quarter was down 29.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.33) earnings per share.
XON stock traded down $2.45 during trading on Friday, hitting $10.77. 2,685,397 shares of the company’s stock traded hands, compared to its average volume of 1,557,050. Intrexon has a 1 year low of $10.26 and a 1 year high of $20.16.
In related news, SVP Joel D. Liffman sold 79,000 shares of Intrexon stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $14.59, for a total transaction of $1,152,610.00. Following the transaction, the senior vice president now directly owns 79,500 shares of the company’s stock, valued at $1,159,905. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 48.20% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new position in Intrexon during the third quarter valued at approximately $131,000. BB&T Securities LLC purchased a new position in Intrexon during the second quarter valued at approximately $175,000. Chessman Wealth Strategies RIA purchased a new position in Intrexon during the second quarter valued at approximately $205,000. John G Ullman & Associates Inc. purchased a new position in Intrexon during the third quarter valued at approximately $258,000. Finally, Metropolitan Life Insurance Co. NY increased its holdings in Intrexon by 477.9% during the second quarter. Metropolitan Life Insurance Co. NY now owns 23,140 shares of the biotechnology company’s stock valued at $323,000 after buying an additional 19,136 shares during the period. 84.92% of the stock is currently owned by institutional investors.
XON has been the topic of a number of research reports. Bank of America lowered shares of Intrexon from a “neutral” rating to an “underperform” rating and set a $12.00 target price on the stock. in a research report on Monday, July 16th. Stifel Nicolaus initiated coverage on shares of Intrexon in a research report on Tuesday, July 17th. They set a “buy” rating and a $72.00 target price on the stock. ValuEngine raised shares of Intrexon from a “strong sell” rating to a “sell” rating in a research report on Monday, August 20th. Zacks Investment Research lowered shares of Intrexon from a “buy” rating to a “hold” rating in a research report on Monday, July 16th. Finally, JMP Securities raised their target price on shares of Intrexon from $42.00 to $43.00 and gave the stock a “market outperform” rating in a research report on Wednesday, October 10th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $29.67.
TRADEMARK VIOLATION NOTICE: “Intrexon (XON) Releases Earnings Results, Misses Estimates By $0.21 EPS” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2018/11/09/intrexon-xon-releases-earnings-results-misses-estimates-by-0-21-eps.html.
Intrexon Company Profile
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.